Cargando…

Prolonged-release melatonin for insomnia – an open-label long-term study of efficacy, safety, and withdrawal

BACKGROUND: Prolonged-release melatonin (PRM) 2 mg is indicated for insomnia in patients aged 55 years and older. A recent double-blind placebo-controlled study demonstrated 6-month efficacy and safety of PRM in insomnia patients aged 18–80 and lack of withdrawal and rebound symptoms upon discontinu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lemoine, Patrick, Garfinkel, Doron, Laudon, Moshe, Nir, Tali, Zisapel, Nava
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150476/ https://www.ncbi.nlm.nih.gov/pubmed/21845053 http://dx.doi.org/10.2147/TCRM.S23036

Ejemplares similares

Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study
por: Garfinkel, Doron, et al.
Publicado: (2011)

Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety
por: Wade, Alan G, et al.
Publicado: (2010)

Efficacy and safety of prolonged-release melatonin for insomnia in middle-aged and elderly patients with hypertension: a combined analysis of controlled clinical trials
por: Lemoine, Patrick, et al.
Publicado: (2012)

Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder
por: Maras, Athanasios, et al.
Publicado: (2018)

Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer’s disease: a 6-month, randomized, placebo-controlled, multicenter trial
por: Wade, Alan G, et al.
Publicado: (2014)

Prolonged release melatonin for improving sleep in totally blind subjects: a pilot placebo-controlled multicenter trial
por: Roth, Thomas, et al.
Publicado: (2015)

Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials
por: Grossman, Ehud, et al.
Publicado: (2011)

Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin
por: Hajak, Göran, et al.
Publicado: (2015)

Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder
por: Malow, Beth A., et al.
Publicado: (2020)

Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver’s Quality of Life
por: Schroder, Carmen M., et al.
Publicado: (2019)

New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation
por: Zisapel, Nava
Publicado: (2018)

New approaches in the management of insomnia: weighing the advantages of prolonged-release melatonin and synthetic melatoninergic agonists
por: Hardeland, Rüdiger
Publicado: (2009)

PT655. The effectiveness of prolonged-release melatonin among primary insomnia patients whose sleep schedule was set
por: Park, Boram, et al.
Publicado: (2016)

Therapeutic Effects of Melatonin Receptor Agonists on Sleep and Comorbid Disorders
por: Laudon, Moshe, et al.
Publicado: (2014)

Bioavailability of Oniria(®), a Melatonin Prolonged-Release Formulation, Versus Immediate-Release Melatonin in Healthy Volunteers
por: Román Martinez, Manuel, et al.
Publicado: (2022)

Melatonin, but not melatonin receptor agonists Neu-P11 and Neu-P67, attenuates TNBS-induced colitis in mice
por: Zielińska, Marta, et al.
Publicado: (2016)

Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study
por: Bologna, Carolina, et al.
Publicado: (2021)

PM351. Efficacy and Safety of Sansoninto for Insomnia in Child and Adolescent Patients: An Open-Label Study
por: Miyaoka, Tsuyoshi, et al.
Publicado: (2016)

Prolonged–release melatonin in patients with idiopathic REM sleep behavior disorder
por: Jun, Jin‐Sun, et al.
Publicado: (2019)

Prolonged–release melatonin in patients with idiopathic REM sleep behavior disorder
Publicado: (2019)

Melatonin for Insomnia in Medical Inpatients: A Narrative Review
por: Salahub, Christine, et al.
Publicado: (2022)

Melatonin Treatment for Pediatric Patients with Insomnia: Is There a Place for It?
por: Rolling, Julie, et al.
Publicado: (2022)

Dissolution of Intact, Divided and Crushed Circadin Tablets: Prolonged vs. Immediate Release of Melatonin
por: Chua, Hui Ming, et al.
Publicado: (2016)

Safety and Efficacy of Once-Daily Prolonged-Release Tacrolimus in Living Donor Liver Transplantation: An Open-Label, Prospective, Single-Arm, Phase 4 Study
por: Lee, Eung Chang, et al.
Publicado: (2018)

Effectiveness and safety of tapentadol prolonged release with tapentadol immediate release on-demand for the management of severe, chronic osteoarthritis-related knee pain: results of an open-label, phase 3b study
por: Steigerwald, Ilona, et al.
Publicado: (2012)

Efficacy and safety of prolonged-release versus immediate-release tacrolimus in de novo liver transplant recipients in South Korea: a randomized open-label phase 4 study (MAPLE)
por: Kim, Myoung Soo, et al.
Publicado: (2019)

Withdrawing and Withholding Life-Prolonging Medical Treatment
por: Jessiman, Ian
Publicado: (2000)

Bioavailability of Melatonin after Administration of an Oral Prolonged-Release Tablet and an Immediate-Release Sublingual Spray in Healthy Male Volunteers
por: Ait Abdellah, Samira, et al.
Publicado: (2023)

Safety and Efficacy of Reduced Prolonged-release Tacrolimus Exposure in De Novo Kidney Transplantation: A Randomized, Open-label, Pilot Study in Asia—OPTIMIZE Study
por: Kim, Young Hoon, et al.
Publicado: (2019)

Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatments
por: Bertholet-Thomas, Aurélia, et al.
Publicado: (2020)

Trial protocol of an open label pilot study of lisdexamfetamine for the treatment of acute methamphetamine withdrawal
por: Acheson, Liam S., et al.
Publicado: (2022)

Efficacy and safety of controlled-release oxycodone for the management of moderate-to-severe chronic low back pain in Japan: results of an enriched enrollment randomized withdrawal study followed by an open-label extension study
por: Kawamata, Mikito, et al.
Publicado: (2019)

Zolpidem modified-release in insomnia
por: Kirkwood, Cynthia, et al.
Publicado: (2007)

Suvorexant for insomnia in patients with psychiatric disorder: A 1‐week, open‐label study
por: Kishi, Taro, et al.
Publicado: (2019)

A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome
por: Girish, K., et al.
Publicado: (2016)

Low Doses of Melatonin to Improve Sleep in Children with ADHD: An Open-Label Trial
por: Checa-Ros, Ana, et al.
Publicado: (2023)

Efficacy and safety of prolonged‐release tacrolimus in stable pediatric allograft recipients converted from immediate‐release tacrolimus – a Phase 2, open‐label, single‐arm, one‐way crossover study
por: Rubik, Jacek, et al.
Publicado: (2019)

Withdrawing life-prolonging medical treatment in 246 patients
por: Nolin, T
Publicado: (2000)

Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinson’s disease: a preliminary evidence
por: Liguori, Claudio, et al.
Publicado: (2022)

The Effects of Magnesium – Melatonin - Vit B Complex Supplementation in Treatment of Insomnia
por: Djokic, Gorica, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t4b4pgv0mjffuiab0aj0n476n9